BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22834417)

  • 1. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
    Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
    Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estrogens/Medroxyprogesterone Acetate on Breast Cancer Gene Expression in Healthy Postmenopausal Women.
    Lalitkumar PGL; Lundström E; Byström B; Ujvari D; Murkes D; Tani E; Söderqvist G
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women.
    Murkes D; Conner P; Leifland K; Tani E; Beliard A; Lundström E; Söderqvist G
    Fertil Steril; 2011 Mar; 95(3):1188-91. PubMed ID: 21067727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmenopausal hormone therapy and change in mammographic density.
    Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
    J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
    Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
    Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.
    Panay N; Nappi RE; Stute P; Palacios S; Paszkowski T; Kagan R; Archer DF; Héroux J; Boolell M
    Maturitas; 2023 Jun; 172():23-31. PubMed ID: 37084589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study.
    Files JA; Miller VM; Cha SS; Pruthi S
    J Womens Health (Larchmt); 2014 Oct; 23(10):801-5. PubMed ID: 25268853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of oral conjugated equine estrogens and micronized 17beta-estradiol on breast proliferation: a retrospective analysis.
    Wood CE; Clarkson TB; Chen H; Veenstra TD; Xu X; Scott L; Cline JM
    Menopause; 2008; 15(5):890-8. PubMed ID: 18520696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women.
    Saure A; Planellas J; Poulsen HK; Jaszczak P
    Maturitas; 2000 Feb; 34(2):133-42. PubMed ID: 10714908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate.
    Lundström E; Virijevic I; Söderqvist G
    Horm Mol Biol Clin Investig; 2020 Jul; 41(3):. PubMed ID: 32735552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.
    Cline JM; Soderqvist G; von Schoultz E; Skoog L; von Schoultz B
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):93-100. PubMed ID: 8572040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
    Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
    Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
    Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
    Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
    Yasui T; Uemura H; Tomita J; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
    Menopause; 2006; 13(4):651-9. PubMed ID: 16837887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers.
    Blondon M; van Hylckama Vlieg A; Wiggins KL; Harrington LB; McKnight B; Rice KM; Rosendaal FR; Heckbert SR; Psaty BM; Smith NL
    J Thromb Haemost; 2014 Jun; 12(6):879-86. PubMed ID: 24628832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.
    Valdivia I; Campodónico I; Tapia A; Capetillo M; Espinoza A; Lavín P
    Fertil Steril; 2004 Mar; 81(3):617-23. PubMed ID: 15037411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.